血管活性肠肽可改善大鼠肺移植中的再灌注损伤。

Nagahiro I, Yano M, Boasquevisque C H, Fujino S, Cooper J D, Patterson G A

Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.

J Heart Lung Transplant. 1998 Jun;17(6):617-21.

BACKGROUND

Vasoactive intestinal peptide (VIP) has been reported to have some properties that provide protection from lung injury. Furthermore, its protective effect in cold storage of donor lungs has been confirmed. We examined its effect and the timing of administration in an in vivo rat lung transplantation model.

METHODS

All lungs were flushed with low-potassium dextran-1% glucose solution, and orthotopic left lung transplantations were performed. Rats were divided into four groups (n = 6). Group I received no preservation or storage. Groups II, III, and IV grafts were stored for 18 hours at 4 degrees C. Group II received no VIP. Group III received VIP (0.1 g/ml) via the flush solution. Group IV recipients received VIP (3 microg/kg) intravenously just after reperfusion. Twenty-four hours after transplantation, the right main pulmonary artery and right main bronchus were ligated, and the rats were ventilated with 100% O2 for 5 minutes. Mean pulmonary arterial pressure, peak airway pressure, blood gas analysis, serum lipid peroxide level, tissue myeloperoxidase activity, and wet-dry weight ratio were measured.

RESULTS

The partial O2 tension values of groups III and IV were better than group II (groups II, III, and IV: 147.4 +/- 71.4, 402.1 +/- 64.8, 373.4 +/- 81.0 mm Hg; p < 0.05). Peak airway pressure was lower in groups III and IV than in group II (groups II, III, and IV: 19.7 +/- 0.8, 16.7 +/- 0.9. and 16.3 +/- 1.0 mm Hg; p < 0.05). Mean pulmonary arterial pressure in group III was lower than group II (groups II and III: 36.3 +/- 3.0 and 22.1 +/- 2.2 mm Hg; p < 0.01). Wet-dry weight ratio in group III was lower than in groups II and IV (group II, III, and IV: 5.2 +/- 0.2, 4.4 +/- 0.2, and 5.2 +/- 0.3; II vs III; p < 0.05, III vs IV; p < 0.01). Serum lipid peroxide levels in groups III and IV were significantly lower (groups II, III, and IV: 2.643 +/- 0.913, 0.455 +/- 0.147, and 0.325 +/- 0.124 nmol/ml; p < 0.01).

CONCLUSION

VIP ameliorates reperfusion injury in an in vivo rat lung transplantation model. Either administration of VIP via the flush solution or systemically just after reperfusion was associated with improved pulmonary function.

背景

据报道，血管活性肠肽（VIP）具有一些可预防肺损伤的特性。此外，其在供体肺冷保存中的保护作用已得到证实。我们在大鼠体内肺移植模型中研究了其作用及给药时机。

方法

所有肺均用低钾右旋糖酐 - 1%葡萄糖溶液冲洗，并进行原位左肺移植。将大鼠分为四组（n = 6）。第一组未进行保存或储存。第二、三、四组的移植物在4℃下储存18小时。第二组未接受VIP。第三组通过冲洗液接受VIP（0.1 g/ml）。第四组受体在再灌注后立即静脉注射VIP（3μg/kg）。移植后24小时，结扎右主肺动脉和右主支气管，并用100%氧气对大鼠进行通气5分钟。测量平均肺动脉压、气道峰值压力、血气分析、血清脂质过氧化物水平、组织髓过氧化物酶活性以及湿干重比。

结果

第三组和第四组的部分氧分压值优于第二组（第二、三、四组：147.4±71.4、402.1±64.8、373.4±81.0 mmHg；p < 0.05）。第三组和第四组的气道峰值压力低于第二组（第二、三、四组：19.7±0.8、16.7±0.9和16.3±1.0 mmHg；p < 0.）。第三组的平均肺动脉压低于第二组（第二组和第三组：36.3±3.0和22.1±2.2 mmHg；p < 0.01）。第三组的湿干重比低于第二组和第四组（第二、三、四组：5.2±0.2、4.4±0.2和5.2±0.3；第二组与第三组比较，p < 0.05；第三组与第四组比较，p < 0.01）。第三组和第四组的血清脂质过氧化物水平显著降低（第二、三、四组：2.643±0.913、0.455±0.147和0.325±0.124 nmol/ml；p < 0.01）。